Friedman succeeds R. Douglas Norby, who has retired as a director following 18 years of service to the company.
Friedman is a veteran of the biotech industry with deep experience in research, and both early and late clinical development.
Over his more than 40-year career, he has established a strong track record of building and leading R and D organisations, successfully expanding their pipelines of assets, overseeing the commercial development of innovative therapeutic products across a range of areas, and building shareholder value.
Friedman served as president and chief executive officer of Incyte Corp. from 2001-2014 where he led a transformation of the business from genomics to a therapeutic focus establishing its foundation as a leader in oncology. He continues to serve on Incyte's board of directors.
Currently, Friedman serves as chairman and chief executive officer of Madrigal Pharmaceuticals, Inc., following its merger with Synta Pharmaceuticals Corp.
In July 2016. Earlier in his career, he held executive and R and D positions with DuPont Pharmaceuticals Research Laboratories, Merck Research Laboratories and Merck Sharp and Dohme Corp.
Friedman received his M.D. from Harvard Medical School and his B.S. in Biology from Princeton University.
Alexion also announced that director Alvin S. Parven advised the board that he does not plan to stand for re-election at the company's next annual meeting of shareholders following 18 years of service as an Alexion director.
The board of directors has retained Spencer Stuart to conduct a search for an additional new director.
Alexion is focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders.
The company has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer